Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy.

Ronald M Witteles¹, Haechung Chung², Feng Dai², Cynthia Gutierrez³, Andrew Rava³, Sameer Swarup⁴, Abbas Ebrahim², Cindi Pankratova²

¹Division of Cardiovascular Medicine and Stanford Amyloid Center, Stanford University School of Medicine, Stanford, CA, United States.

²Pfizer, New York, NY, United States.

³Genesis Research Group, Hoboken, NJ, United States.

⁴Clarify Health Solutions, New York, NY, United States.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Most patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) are diagnosed noninvasively, using nuclear imaging and monoclonal protein testing. However, concerns have been raised that some may receive an ATTRwt-CM diagnosis based on incomplete evaluations (not based on current consensus recommendations). Using a cohort of US Medicare Fee-for-Service patients, we aimed…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.